Abstract:The epidermal growth factor receptor (EGFR) is overexpressed in many epithelial cancers, an observation often correlated with poor clinical outcome. Overexpression of the EGFR is commonly caused by EGFR gene amplification and is sometimes associated with expression of a variant EGFR (de2-7 EGFR or EGFRvIII) bearing an internal deletion in its extracellular domain. Monoclonal antibody (mAb) 806 is a novel EGFR antibody with significant antitumor activity that recognizes both the de2-7 EGFR and a subset of the wild type (wt) EGFR when overexpressed but does not bind the wt EGFR expressed in normal tissues. Despite only binding to a low proportion of the wt EGFR expressed in A431 tumor cells (approximately 10%), mAb 806 displays robust antitumor activity against A431 xenografts grown in nude mice. To elucidate the mechanism leading to its unique specificity and mode of antitumor activity, we have determined the EGFR binding epitope of mAb 806. Analysis of mAb 806 binding to EGFR fragments expressed either on the surface of yeast or in an immunoblot format identified a disulfide-bonded loop (amino acids 287-302) that contains the mAb 806 epitope. Indeed, mAb 806 binds with apparent high affinity (approximately 30 nm) to a synthetic EGFR peptide corresponding to these amino acids. Analysis of EGFR structures indicates that the epitope is fully exposed only in the transitional form of the receptor that occurs because EGFR changes from the inactive tethered conformation to a ligand-bound active form. It would seem that mAb 806 binds this small proportion of transient receptors, preventing their activation, which in turn generates a strong antitumor effect. Finally, our observations suggest that the generation of antibodies to transitional forms of growth factor receptors may represent a novel way of reducing normal tissue targeting yet retaining antitumor activity.

Epidermal Growth Factor Receptor (EGFR) Inhibitors Screened from Autodisplayed Fv-Antibody Library

Monocarboxylate transporter-1 (MCT-1) inhibitors screened from autodisplayed FV-antibody library

In-silico screening of inhibitor on protein epidermal growth factor receptor (EGFR)

Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor

Discovery of potent allosteric antibodies inhibiting EGFR

Discovery of Novel Epidermal Growth Factor Receptor (EGFR) Inhibitors Using Computational Approaches

Screening and Characterization of Inhibiting Peptides Binding to the Tumor Vascular Growth Factor Receptor

Semi-Automated Cell Panning for Efficient Isolation of FGFR3-Targeting Antibody

Analysis of EGFR binding hotspots for design of new EGFR inhibitory biologics

[Selection and Characterization of Human Antibodies Against Vascular Endothelial Growth Factor from Human Phage Display Antibody Library].

Antibody Library Screening Using Yeast Biopanning and Fluorescence-Activated Cell Sorting

A bispecific decoy receptor VEGFR-EGFR/Fc binding EGF-like ligands and VEGF shows potent antitumor efficacy

Identification of Vinyl Sulfone Derivatives as EGFR Tyrosine Kinase Inhibitor: In Vitro and In Silico Studies

Expression and purification of the human epidermal growth factor receptor extracellular domain

Preliminary Discovery of Small Molecule Inhibitors of Epidermal Growth Factor Receptor (EGFR) That Bind to the Extracellular Domain

Phage antibody library screening for the selection of novel high-affinity human single-chain variable fragment against gastrin receptor: an in silico and in vitro study

Discovery of Cyclic Peptidomimetic Ligands Targeting the Extracellular Domain of EGFR

Frontal Affinity Chromatography Combined On-Line with Mass Spectrometry: a Tool for the Binding Study of Different Epidermal Growth Factor Receptor Inhibitors.

Search for potentially biased epidermal growth factor receptor (EGFR) inhibitors through pharmacophore modelling, molecular docking, and molecular dynamics (MD) simulation approaches

Searching for EGF Fragments Recreating the Outer Sphere of the Growth Factor Involved in Receptor Interactions

Proximity extracellular protein-protein interaction analysis of EGFR using AirID-conjugated fragment of antigen binding